CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has been named one of the Best Places to Work in Massachusetts by the The Boston Business Journal in its eleventh annual regional awards program. The honor recognizes the Company’s achievements in creating a positive work environment that attracts and retains employees through a combination of employee satisfaction, working conditions and company culture.
InVivo Therapeutics was one of over 400 companies to qualify for consideration based on a two-stage nomination process and the results of employee-satisfaction surveys taken throughout March and April.
“For years, my biggest concern has been managing rapid growth without experiencing a bottleneck in human resources,” said Frank Reynolds, InVivo Chief Executive Officer. “In early 2012, we had approximately ten employees, and already we knew that we would be going through intense hiring periods, possibly adding as many as two hundred employees in a quarter. At that point, we partnered with the architects and designers at Kling Stubbins to build a new headquarters in Kendall Square and become the world’s most advanced neurotrauma research center. We now have more than fifty staff members, and are still going strong. We hit a grand slam with the new headquarters and created an innovative, exciting, and collaborative corporate culture that has already resulted in the addition of six more products to our pipeline.”
Continued Reynolds, “Fostering employee development is at the core of our mission. My employees know that the Company will do just about anything to support their success, and I’m very proud of everyone at InVivo; they’re the reason we’ve been recognized by the Boston Business Journal.”
“Our Best Places to Work event will again recognize the importance of cultivating a great workplace culture as a competitive advantage," said Chris McIntosh, publisher of The Boston Business Journal. "Companies on our list can be justifiably proud of creating a high level of workplace satisfaction during an economy where traditional rewards like big raises and bonuses aren't as easy to give. In good times and in bad, our results validate how the creation of the right corporate culture can create powerful business advantages. Employees are proud to work for companies that are about more than just business.”
The survey project was launched in January by The Boston Business Journal in conjunction with market research firm Quantum Workplace of Omaha, NE. Companies were evaluated on the results of more than 18,000 employee-satisfaction surveys. Employees answered questionnaires that addressed such factors as their pride in the company, company encouragement, support and recognition of achievement and relationships with co-workers and supervisors. The results were analyzed and scored by assigning points to each question. The top 25 companies in three size categories plus the top 5 in a new category called “PR/Communications” will be awarded during a lively cocktail reception on June 13th at the iconic CitiCenter/Wang Theatre and profiled in a special supplement of The Boston Business Journal on June 14th.
For more event details, please visit http://www.bizjournals.com/boston/event/76851.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
About the Boston Business Journal
The Boston Business Journal is Greater Boston’s leading source of business news, information and events, reaching readers through the weekly print publication, the website bostonbusinessjournal.com and e-mail products. The BBJ also prints the annual Book of Lists — the region’s top resource for business decision-makers seeking information about potential clients, suppliers and partners.
The Boston Business Journal is published by American City Business Journals, the nation’s largest publisher of metropolitan business news.
Safe Harbor Statement
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.